
|Videos|January 3, 2018
Dr. Abou-Alfa on Checkpoint Inhibitors in Liver Cancer
Author(s)Ghassan K. Abou-Alfa, MD
Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses checkpoint inhibitors in liver cancer.
Advertisement
Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses checkpoint inhibitors in liver cancer.
There is a place for checkpoint inhibitors in liver cancer, says Ghassan, but currently he chooses tyrosine kinase inhibitor (TKI) therapy. Upcoming data with checkpoint inhibitors will read out soon and will affect sequencing, he adds.
Additionally, Abou-Alfa says that there may be potential for chimeric antigen receptor (CAR) T-cell therapy in the treatment of liver cancer, but data are not currently available.
Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Outcomes With Bridging Therapy Correlate With Cilta-Cel Efficacy, Safety in Multiple Myeloma
4
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
5






































